Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway - Chen, H; Zhang, Q; Zhang, Y; Jia, B; Zhang, B; Wang, C (OncoTargets Ther, 2018)